A Phase 2 interventional study of Cyclophosphamide and Fludarabine in Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-02.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 11 under way, none of them phase 3. Cyclophosphamide · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 95th largest by enrollment of the 145 interventional ones that give a count, is one of 7 that started in 2006, is one of 100 in phase 2, and was the 133rd registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →3 of the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages up to 75
By country, each count listing its studies:
Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →
Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 114 · Phase 3 11 · Phase 4 3
First in 1988; this study’s year is marked. 7 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 49 across the 145 interventional studies. Of the 132 that completed or were terminated, 77 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 155 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche: 1 open now, 2 under way, none of them phase 3. Of 46 finished, 28 (61%) have results posted.
Among the 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche, this one is the 32nd largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2006, is one of 13 in phase 2, and was the 41st registered.
Hoffmann-La Roche’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2003.
4 of the studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00466531Memorial Sloan Kettering Cancer CenterTreatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | 2026-12 |
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
| NCT02153580City of Hope Medical CenterCellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | 2027-08-11 |
| NCT05805605Masonic Cancer Center, University of MinnesotaAllo HSCT Using RIC and PTCy for Hematological Diseases | 2027-10-22 |
Add all 4 to your calendar (.ics) → With an account.
Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Hoffmann-La Roche’s 48 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of rituximab in combination with chemotherapy (fludarabine and cyclophosphamide) in participants with B-cell CLL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive rituximab (375 milligrams per meter-squared \[mg/m\^2\] intravenously \[IV\]) on Cycle 1 Day 1, followed by fludarabine (25 mg/m\^2 once daily IV) and cyclophosphamide (250 mg/m\^2 once daily IV) for Days 2 to 4 of Cycle 1. Then rituximab (500 mg/m\^2 IV) will be administered on Day 1 of Cycles 2 to 6, followed by IV fludarabine (25 mg/m\^2 once daily IV) and cyclophosphamide (250 mg/m\^2 once daily IV) on Days 1 to 3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length, and the overall duration of treatment will be approximately 6 months.
Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Rituximab
Cyclophosphamide will be administered IV at 250 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
Fludarabine will be administered IV at 25 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
Rituximab will be administered IV at 375 mg/m\^2 on Day 1 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
Also known as: MabThera/Rituxan
Percentage of Participants With Death or Disease Progression
Treatment response was monitored throughout the study and assessed using standardized criteria. Disease progression was defined as the occurrence of at least one of the following: greater than or equal to (≥) 50 percent (%) increase in the longest diameter of at least two enlarged lymph nodes, increase in spleen and/or liver size by at least 2 centimeters (cm) from Baseline as determined by measurement below the costal margin, or ≥50% increase in the number of circulating lymphocytes. The percentage of participants with death or documented disease progression at any time during the study was calculated.
Time frame: Up to 5 years (from Baseline until disease progression or death, whichever occurred first)
Progression-Free Survival (PFS)
Treatment response was monitored throughout the study and assessed using standardized criteria. Disease progression was defined as the occurrence of at least one of the following: ≥50% increase in the longest diameter of at least two enlarged lymph nodes, increase in spleen and/or liver size by at least 2 cm from Baseline as determined by measurement below the costal margin, or ≥50% increase in the number of circulating lymphocytes. PFS was defined as the time from study inclusion until first event of disease progression or death and was estimated using Kaplan-Meier analysis.
Time frame: Up to 5 years (from Baseline until disease progression or death, whichever occurred first)
Percentage of Participants Who Died
Participants were followed for survival throughout the study. The percentage of participants who died of any cause during the study was calculated.
Time frame: Up to 5 years (from Baseline until death)
Overall Survival (OS)
Participants were followed for survival throughout the study. OS was defined as the time from study inclusion until death from any cause and was estimated using Kaplan-Meier analysis
Time frame: Up to 5 years (from Baseline until death)
Percentage of Participants With Complete Response (CR), Nodular Partial Response (nPR), or Partial Response (PR)
Treatment response was monitored throughout the study and assessed using standardized criteria. CR was defined as hemoglobin ≥11 grams per deciliter (g/dL), lymphocytes less than (\<) 4000 cells per cubic millimeter (cells/mm\^3), neutrophils greater than (\>) 1500 cells/mm\^3, platelets \>100,000 cells/mm\^3, bone marrow (BM) biopsy with \<30% lymphocytes with no lymphocytic infiltrates, no evidence of lymphoid nodules on physical exam, and performance status of 0. PR was defined as \>50% decrease in size of enlarged lymph nodes, hepatomegaly, and splenomegaly, with peripheral counts meeting the same criteria as CR or ≥50% improvement from pre-treatment values. Participants with lymphoid nodules on BM biopsy who otherwise met CR criteria were considered nPR. The percentage of participants with each level of best overall response was calculated.
Time frame: Up to 4 years (assessed every 3 months during 6-month treatment period, every 2 months during 6-month safety follow-up, then every 3 months during 3-year safety follow-up)
| Milestone | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Started | 34 |
| Completed | 23 |
| Not completed | 11 |
| Withdrew: Adverse event/intercurrent disease | 3 |
| Withdrew: Death | 5 |
| Withdrew: Insufficient response/progressed disease | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Violation of selection criteria | 1 |
Treatment response was monitored throughout the study and assessed using standardized criteria. Disease progression was defined as the occurrence of at least one of the following: greater than or equal to (≥) 50 percent (%) increase in the longest diameter of at least two enlarged lymph nodes, increase in spleen and/or liver size by at least 2 centimeters (cm) from Baseline as determined by measurement below the costal margin, or ≥50% increase in the number of circulating lymphocytes. The percentage of participants with death or documented disease progression at any time during the study was calculated.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Percentage of Participants With Death or Disease Progression | 24 |
Treatment response was monitored throughout the study and assessed using standardized criteria. Disease progression was defined as the occurrence of at least one of the following: ≥50% increase in the longest diameter of at least two enlarged lymph nodes, increase in spleen and/or liver size by at least 2 cm from Baseline as determined by measurement below the costal margin, or ≥50% increase in the number of circulating lymphocytes. PFS was defined as the time from study inclusion until first event of disease progression or death and was estimated using Kaplan-Meier analysis.
| months | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Progression-Free Survival (PFS) | 47.2 (42.2 to 52.2) |
Participants were followed for survival throughout the study. The percentage of participants who died of any cause during the study was calculated.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Percentage of Participants Who Died | 14 |
Participants were followed for survival throughout the study. OS was defined as the time from study inclusion until death from any cause and was estimated using Kaplan-Meier analysis
| months | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Overall Survival (OS) | 49.5 (44.8 to 54.2) |
Treatment response was monitored throughout the study and assessed using standardized criteria. CR was defined as hemoglobin ≥11 grams per deciliter (g/dL), lymphocytes less than (\<) 4000 cells per cubic millimeter (cells/mm\^3), neutrophils greater than (\>) 1500 cells/mm\^3, platelets \>100,000 cells/mm\^3, bone marrow (BM) biopsy with \<30% lymphocytes with no lymphocytic infiltrates, no evidence of lymphoid nodules on physical exam, and performance status of 0. PR was defined as \>50% decrease in size of enlarged lymph nodes, hepatomegaly, and splenomegaly, with peripheral counts meeting the same criteria as CR or ≥50% improvement from pre-treatment values. Participants with lymphoid nodules on BM biopsy who otherwise met CR criteria were considered nPR. The percentage of participants with each level of best overall response was calculated.
| percentage of participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| CR | 71 |
| nPR | 9 |
| PR | 18 |
Collected over Up to 4 years (assessed every 4 weeks during 6-month treatment period, every 2 months during 6-month safety follow-up, then every 3 months during 3-year safety follow-up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab + Fludarabine + Cyclophosphamide | — | 15/34 (44.1%) | 18/34 (52.9%) |
| Event | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Febrile neutropeniaInfections and infestations | 7/34 |
| NeutropeniaBlood and lymphatic system disorders | 5/34 |
| FeverGeneral disorders | 3/34 |
| AnemiaBlood and lymphatic system disorders | 1/34 |
| Abdominal painGastrointestinal disorders | 1/34 |
| DeathGeneral disorders | 1/34 |
| Infusion related reactionGeneral disorders | 1/34 |
| Bronchial infectionInfections and infestations | 1/34 |
| SepsisInfections and infestations | 1/34 |
| Neoplasm (colon)Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/34 |
| Event | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Low plateletsBlood and lymphatic system disorders | 10/34 |
| AnemiaBlood and lymphatic system disorders | 8/34 |
| Skin infectionInfections and infestations | 7/34 |
| LeukopeniaBlood and lymphatic system disorders | 6/34 |
| HypogammaglobulinemiaBlood and lymphatic system disorders | 6/34 |
All Participants Enrolled: All participants who complied with selection criteria at enrollment.
| Age, Continuous(years) | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Mean | 60.3 ± 8.8 |
| Sex: Female, Male(Participants) | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Female | 5 |
| Male | 29 |
The record gives a start of Feb 2006, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclophosphamide · Fludarabine · Rituximab
Leukemia, Lymphocytic, Chronic, B-Cell →